Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells. (VISNU-1)

NCT01640405 Phase 3 COMPLETED

The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.

Details

Lead sponsor	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase	Phase 3
Status	COMPLETED
Enrolment	350
Start date	2012-07
Completion	2018-11

Conditions

• Metastatic Colorectal Cancer

Interventions

• modified FOLFOX6 + bevacizumab
• FOLFOXIRI + Bevacizumab

Primary outcomes

• Progression free survival (PFS) — 5 years

Countries

Spain